FTRE:NSD-Fortrea Holdings Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 36.35

Change

0.00 (0.00)%

Market Cap

USD 2.49B

Volume

0.41M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.34 (-0.31%)

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

+7.68 (+0.79%)

USD 96.94B
MRNA Moderna Inc

+2.65 (+2.11%)

USD 44.96B
BNTX BioNTech SE

-0.44 (-0.47%)

USD 22.34B
ARGX argenx NV ADR

-3.47 (-0.97%)

USD 22.28B
ALNY Alnylam Pharmaceuticals Inc

-2.00 (-1.33%)

USD 19.03B
GMAB Genmab AS

+0.37 (+1.27%)

USD 18.26B
RPRX Royalty Pharma Plc

-0.31 (-1.09%)

USD 16.73B
BGNE BeiGene Ltd

-1.40 (-0.86%)

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

-0.85 (-1.06%)

USD 15.35B

ETFs Containing FTRE

PSCH Invesco S&P SmallCap Heal.. 2.69 % 0.29 %

+0.40 (+0.93%)

USD 0.20B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.15% 63% D 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.15% 63% D 67% D+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.49B 92% A 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector